Lumosa Therapeutics (6535) Fundamentals 2026 — Revenue Analysis | SniperIQ
Lumosa Therapeutics (6535) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Market CapNT
Net Margin-1133.2%
Revenue (FY25)NT
6MFull research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lumosa Therapeutics's market cap?
Lumosa Therapeutics (6535) has a market capitalization of approximately NT
What is Lumosa Therapeutics's P/E ratio?
Lumosa Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 10.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lumosa Therapeutics?
Lumosa Therapeutics runs a net profit margin of -1133.2%, a gross margin of 58.9%, and an operating margin of -934.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lumosa Therapeutics generate?
Lumosa Therapeutics reported revenue of NT